Toyota Motor Corp vs TransMedics Group Inc — how do they compare? Toyota Motor Corp trades at $188.5 (market cap $221.79B), while TransMedics Group Inc trades at $86.43 (market cap $3.10B). The key difference: Toyota Motor Corp is far larger — about 71.5× TransMedics Group Inc's market cap, and Toyota Motor Corp pays a 3.3% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TM | TMDX | |
|---|---|---|
Market Cap | $221.79B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $248.29 | $150.42 |
52-Week Low | $166.50 | $61.99 |
Enterprise Value | $414.06B | $3.49B |
Dividend Yield | 3.3% | — |
Signals from Pluang's Aura AI — not financial advice
Toyota Motor (TM) trades at $188.97, up 0.1% on the day, with a bullish technical signal from moving averages. The stock presents attractive valuation metrics, including a P/E of 8.53 and P/B of 0.95, trading below book value. Recent quarterly earnings have consistently beaten expectations, though Q1 2026 results missed estimates due to higher costs, as reported by Zacks Investment Research on August 6, 2026. Cash flow trends show volatility, with a net outflow in 2025 but a projected recovery in 2026.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside, but risks include recall costs, China sales weakness, and margin pressure. Institutional sentiment is cautiously optimistic, with no sell ratings among covered analysts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →